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PRedictoRs of functional disability in Patients With chRonic 
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of Pharmaceuitical Education and Research, Mohali, India, 3Postgraduate Institute of Medical 
Education and Research, Chandigarh, India
Objectives: Chronic lumbosacral radicular pain has significant morbidity and burden 
to the society. The objective of this study was to assess the functional disability and 
factors affecting it in patients with chronic lumbosacral radicular pain. MethOds: We 
performed an observational cross sectional study in a public tertiary care hospital in 
north India. Adult patients (18 and 75 years), with > 12 weeks of low back pain, without 
any co-morbidities were included in this study. Data regarding socio-demographics, 
duration of low back pain, prescribing pattern and depression collected at baseline. 
Pain assessed using visual analogue scale (VAS), functional disability using modified 
oswesrty disability questionnaire (MODQ). Patients also asked for health care utiliza-
tion at the end of study. Predictors of high disability were analysed using multivariate 
regression analysis. Results: A total of 246 patients (51% males and 49% females) with 
mean age of 44.9 (12.25) years were included for final analysis. Mean VAS and MODQ 
scores at baseline are 72.3+12.5 and 48.3+11.2 respectively. Based on disability scores, 
62% of patients found to be crippled whereas 62% and 24% of patients fall in severe 
and moderate disability category respectively. VAS and MODQ scores were positively 
correlated (r= 0.84, p< 0.05). Multi factorial analysis reveals that severe pain (higher 
VAS scores), high duration of pain, older age, over-weight, patients from urban region 
and depression were significantly associated with high disability. cOnclusiOns: 
Our study results suggest that chronic lumbosacral radicular pain patients suffer with 
sever disability. Severity of pain was significantly correlated with levels of disability.
PRM3
hieRaRchical netWoRk Meta-analysis incoRPoRating oRdeRing 
constRaints on incReasing doses of inteRventions - aPPlication to 
oveRactive bladdeR syndRoMe
Owen R.K., Tincello D.G., Bujkiewicz S., Abrams K.
University of Leicester, Leicester, UK
bAckgROund: For the conservative treatment of Overactive Bladder (OAB) 
symptoms, the National Institute for Health and Care Excellence (NICE) in the 
UK currently recommends a course of supervised pelvic floor muscle training, 
behavioural therapy, anticholinergic medication, sacral nerve stimulation, and 
more recently, botulinum toxin type A (BoNTA) and Mirabegron. Given the large 
number of interventions and relatively few primary trials, network meta-analy-
ses (NMAs) produce considerable uncertainty in the estimated treatment effects 
and consequently, there is little evidence of the most clinically effective inter-
vention. Objectives: To evaluate the use of hierarchical NMAs incorporating 
ordering constraints on increasing doses in order to identify the most effective 
intervention for the treatment of OAB symptoms. MethOds: Using Bayesian 
Markov Chain Monte Carlo methods, we apply a 3-level hierarchical NMA that 
accounts for both the correlation between treatments within the same class, as 
well as the residual between-study heterogeneity. We further extend this model 
to incorporate ordering constraints on increasing doses of the same interven-
tion. We apply the methods to a dataset obtained from a systematic literature 
review of randomised controlled trials evaluating interventions for OAB syndrome. 
The primary outcomes of interest were mean change from baseline for void-
ing, urgency, and incontinence episodes. Results: The dataset includes 78 trials 
comparing 39 interventions that can be further categorised into 10 classes of 
interventions, including placebo. For voiding, and urgency episodes, BoNTA 200u 
was the most effective intervention with estimated mean reduction of -2.24 (95% 
CrI: -2.95, -1.48), and -2.6 (95% CrI: -3.46, -1.7) episodes relative to placebo, respec-
tively. BoNTA 300u was the most effective intervention for reducing incontinence 
episodes with an estimated mean reduction of -1.81 (95% CrI: -2.39, -1.33) epi-
sodes relative to placebo. cOnclusiOns: Use of hierarchical NMAs, incorporating 
ordering constraints, increases the precision in the effect estimates but maintains 
the interpretability of individual interventions. BoNTA was found to be the most 
effective intervention for reducing symptoms of OAB.
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Objectives: Using randomized clinical trials (RCTs) for clinical decision-making 
necessitates making decisions for individuals based on average treatment effects. 
While many assume important patient variation in treatment effects, identifying 
patients most likely to benefit is problematic. Stratifying patients by their risk 
of the primary outcome was proposed as a method to identify high versus low 
benefit patients. MethOds: From publically available sources, we identified 13 
large RCTs with greater than ~1000 enrollees and overall statistically significant 
results. We derived Cox or logistic regression models using established risk fac-
tors blinded to treatment assignment and stratified the patient population into 
quartiles of risk for the outcome. Treatment effect within each risk quartile was 
estimated on relative and absolute scales. Heterogeneity of treatment effect (HTE) 
was evaluated statistically by testing for an interaction between treatment and 
the linear predictor of risk, and by comparing hazard (or odds) ratios and abso-
lute risk reduction in the extreme risk quartiles. Results: Among 19 unique 
treatment comparisons analyzed, there was no apparent relationship between 
baseline risk and the hazard (or odds) ratios across trials; only 1 of 19 analyses 
had a significant interaction between treatment and baseline risk on the pro-
portional scale. The difference in the log hazard ratio between the extreme risk 
quartiles ranged from -0.89 to 0.60 (median= 0.03; inter-quartile range (IQR) = -0.4-
corticosteroids were more widely used (46.5%/26.8% vs. 12.3%/11.0%) and retinoids 
were less commonly used (5.1% vs. 18.0%). UK physicians were less likely to pre-
scribe a biologic-treatment before trying > = 1 other systemic-treatment (1.8% vs. 8.5%), 
and to wait longer after diagnosis to initiate biologic-therapy (25.8movs. 20.1mo); 
in Germany, patients were more likely to have tried 3-5 other systemic-treatments 
before initiating biologic-treatment (28.0% vs. 14.2%); patients in France were the most 
likely to initiate a biologic without trying another systemic-treatment first (11.2% vs. 
8.5%). Patients in Germany were started on biologics later on average (25.8mo after 
diagnosis vs. 14.0mo). The average flares in past-year was highest in Germany (1.4 
vs. 0.9). Average current PASI-score (26.4 vs. 16.0) and BSA-score (22.8 vs. 19.5) were 
highest in Germany. In France, 41.2% of patients had not had a PASI score done past 
year (vs. 23.3%). In Germany, 56.0% of patients had severe/terminal disease severity 
at biologic-therapy-initiation (vs. 47.8%). cOnclusiOns: Among psoriasis patients 
receiving their first biologic-therapy, treatment patterns and disease severity varied 
across the EU5. Factors influencing the observed variations in treatment patterns and 
outcomes warrant further scrutiny to decrease patient disease burden.
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aPoPtosis and oxidative stRess induced by exPosuRe of MicRoWave 
Radiation in Rat thyMus: ModulatoRy effect of Melatonin
Sokolovic D.1, Sokolovic D.M.2
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Objectives: Exposition to microwave radiation (MW), from mobile phones, satellite 
communications, radio relays, radars and microwave devices in medicine induce 
disturbances in thymus. The pineal secretory product, melatonin (Mel), exerts a 
veriety of effects on the immune system. The aim of the present study was to 
evaluate the effect of melatonin on apoptosis and oxidative stress parametars in 
thymus tissue of rats after 40 days long exposure to MWs. MethOds: Wister rats 
were divided in 4 experimental groups: I (control), II (Mel group) - rats treated with 
Mel every day (2 mg/kg b.w., i.p), III (MW group) - rats exposed to MW (4 h/day), IV 
(MW+Mel) - rats treated with Mel every day (2 mg/kg b.w., i.p) and exposed to MW 
radiation (4 h/day). Ten animals from 4 group were successively sacrificed after 40 
days of the experiment. MW was produced by a mobile test phone (SAR = 0.043-
0.135 W/kg). Results: The current study results demonstrate that MW significantly 
increased thymocyte apoptosis, detected using the Annexin V-FITC/PI detection kit 
(p< 0.001). DNA fragmentation in thymocytes injury of MW is probably triggered by 
the increase activation of alkaline-DNase I (caspase 3-activated) and acid-DNase II 
(p< 0.05). A significant increase in the thymus malondialdehyde (MDA) and carbonyl 
group concentration (p< 0.001), and decreased activity of catalase (p< 0.001) was 
registered during exposure. Melatonin was found to be effective on rat thymocyte: 
(1) decreased apoptotic rate of thymocytes (p< 0.001), (2) effect on terminal apop-
totic reaction, because of the decrease DNase I and DNase II activity (p< 0.01), (3) 
decreased MDA and carbonyl group levels (p< 0.01), (4) increase activity of catalase 
(p< 0.05), comparated with MW group. cOnclusiOns: Having in the mind obtained 
results we can conclude that melatonine exerts protective effects on rat thymocyte 
by preventing apoptosis and oxidative stress disturbances in rats’ thymus under 
exposure of MW.
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Objectives: To explore the existence and clinical implications of symptomatic 
factors in patients with major depressive episodes. MethOds: Data are from a 
6-month prospective, non-interventional, observational study that included 1,549 
MDD patients without sexual dysfunction in twelve countries. Depression severity 
was measured using the Clinical Global Impression (CGI) and the 16-item Quick 
Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Pain and qual-
ity of life were measured using the pain related items of the Somatic Symptom 
Inventory (SSI) and the EuroQoL-5D, respectively. The QIDS-SR16and the SSI items 
were jointly included in a factor analysis. Exploratory factor analysis (EFA) was 
conducted in a randomly selected half of the sample and confirmatory factor 
analysis (CFA) in the remaining half. Results: The EFA showed that a four factor 
model explained the data apropriately (RMSEA 0.041, 90%CI 0.034- 0.048; CFI 0.979). 
The four factors were mood (feeling sad, concentration/decision making, self criti-
cism, suicidal thoughts, interest in people or activities, energy/fatigability, psycho-
motor retardation and agitation); sleep (initial, middle insomnia, early awakening 
and sleeping too much); appetite and weight, and pain (muscle soreness, cramps in 
abdomen, pain in lower back, pain in heart or chest, pain in joints, neck pain, head-
ache). The CFA showed good fit indexes for this four-factor model (RMSA 0.054, 90% 
CI 0.049-0.059; CFI 0.954). There was a highly statistical significant correla-
tion (Spearman) between each of the four factors and CGI severity score and 
quality of life at each of the visits, with higher scores in the factors (higher 
severity) associated with higher CGI and lower quality of life (p< 0.001, all com-
parisons). cOnclusiOns: Considering the results presented, the data reason-
ably support that pain symptoms be included in the evaluation of patients with 
major depression. More severe pain symptoms are associated to higher severity 
of depression and lower quality of life.
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(5.574 exposed and 14.596 not-exposed) were submitted to residential registries. 
The vital status of 96,6% of the study subjects could be confirmed by information 
of the registries. 80,7% were still alive 15 years after the accident (81% exposed, 80% 
not-exposed). 24,6% had died from cancer, 40,9% from cardiovascular diseases and 
31,8% from other causes of death. No effects of the exposure on the vital status 
could be determined (Cox-Regression). In the pharmacoepidemiological case study 
evaluating long term safety of hormone replacement therapy, the survival status of 
2.485 participants was investigated in country-wide residential databases. The vital 
status of 90,8% these participants could be confirmed using the registry information. 
2.250 were still alive after 4-5 years of inclusion into the study, only 6 deaths were 
identified and for only 9% the status could not be determined. cOnclusiOns: 
Official residential registries can be a valuable source for investigating the survival 
status and the causes of death of study subjects in pharmaco- and general epide-
miological studies.
PRM8
RecRuiting MyelofibRosis Patients foR clinical and health outcoMe 
studies using Managed Physician Panels in 5 eu countRies
Eichmann F.1, Potthoff P.1, Brown C.2, Cholmakow-Bodechtel C.1
1Kantar Health Germany, Munich, Germany, 2All Global, London, UK
Objectives: Myelofibrosis (MF) is a chronic blood cancer with an estimated prev-
alence in the US population of 4-5 patients per 100.000 inhabitants. Among the 
sources to recruit MF patients for post-approval studies in a real life environment, 
oncological or cardiological sites are of primary importance. The objective of the 
present contribution is to assess the number of MF patients in these specialties 
and the willingness of the physicians to enroll MF patients for clinical and health 
outcomes studies. MethOds: In 2011, a feasibility survey assessing the incidence 
of MF patients in the sites of 94 oncologists, 72 hematologists and 65 cardiologists in 
5 EU countries (UK, GER, FR, IT, ES) was run, using the All Global managed physician 
panel. The willingness of these specialist groups to participate in clinical and health 
outcomes studies and to recruit patients for these studies was estimated among 
335 oncologists/hematologists and 208 cardiologists. Results: 88% of the oncolo-
gists and 99% of the hematologists treat Myelofibrosis patients (88% oncologists; 
99% hematologists). Cardiologists are involved in MF treatment to a smaller degree 
(75%). In 25% of all practices, less than 10 patients are treated per year, in 36%, 11 
to 50 patients, and in 38%, more than 50. Approximately 90% of the oncologists/
hematologists and 88% of the cardiologists are experienced in clinical and health 
outcomes studies; 80% of the oncologists/hematologists and 60% of the cardiolo-
gists are willing to participate in future studies and 92% resp. 94% in this group 
are willing to enroll patients for clinical and health outcome studies, including 
management of informed consent and ethics procedures as required for the study 
type. cOnclusiOns: Myelofibrosis patients can be successfully recruited for clini-
cal and health outcomes studies using managed panels. Oncologists/hematologists 
and cardiologists are experienced in these study types and willing to participate 
in future studies.
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can gastRic canceR Patients be successfully RecRuited foR clinical 
Phase iii/iv and health outcoMe studies using Managed Physician 
Panels?
Eichmann F.1, Potthoff P.2, Brown C.3
1Kantar Health, Munich, Germany, 2Kantar Health Germany, Munich, Germany, 3All Global, 
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Objectives: Gastric cancer (GC) is a cancer arising from parts of the stomach. To 
recruit GC patients for post-approval studies in a real world environment, oncologi-
cal, hematological, and internist sites might be of primary importance. The present 
contribution assesses the number of GC patients in these sites and the willingness 
of physicians to enroll GC patients for health outcome or clinical phase III/IV studies. 
MethOds: In 2011 a feasibility study about the number of GC patients was run 
in the sites of 63 oncologists, 23 hemato-oncologists and 26 internists in UK (16), 
GER (19), FR (11), IT (27), ES (27), and US (12). Physicians reported about the number 
of “new patients with unresectable, locally advanced or metastatic gastric or gas-
troesophageal junction (GEJ) adenocarcinoma”. The willingness of these specialist 
groups to participate in clinical phase III/IV or health outcome studies was also 
estimated in a different survey. Results: In total these 112 specialists have seen 
approximately 3,200 new gastric cancer patients in the last 6 months. In average 
(median values) oncologists have seen 30 new gastric cancer patients in 6 months, 
hematologists 20 patients and internists 6 patients. Most of the patients (2,600) have 
been treated with chemotherapy. Approximately 90% of the oncologists/hematolo-
gists and 88% of the cardiologists are experienced in clinical phase III/IV or health 
outcome studies; 80% of the oncologists/hematologists and 60% of the cardiologists 
are willing to participate in future studies and 92% resp. 94% in this group are willing 
to enroll patients for clinical phase III/IV or health outcome studies and ask them for 
written informed consent. cOnclusiOns: Patients suffering from Gastric Cancer 
can be successfully recruited for clinical phase III/IV or health outcome studies 
using managed panels. Oncologists/hematologists and cardiologists are usually 
experienced in these studies.
PRM10
assessing the RelationshiP betWeen tReatMent effect and baseline 
Risk in netWoRk Meta-analsysis of ModeRate to seveRe chRonic 
Plaque PsoRiasis tRials
Smiechowski B.1, Cope S.2
1Mapi, Boston, MA, USA, 2Mapi, Toronto, ON, Canada
Objectives: To investigate differences across randomized controlled trials (RCTs) 
evaluating biological therapies for the treatment of moderate to severe chronic 
plaque psoriasis in terms of baseline risk in psoriasis area severity index score (PASI) 
and the association with treatment effects by means of network meta-analysis 
(NMA). MethOds: 25 RCTs reporting the proportion of patients experiencing a 
0.2). However, absolute risk reduction was generally higher in high risk strata, 
ranging from -1.4 to 18.3% (median= 4.6%; IQR= 0.8-6.1%) in quartile one and from 
0.8 to 35.0% (median= 11.5%; IQR= 3.3-19.8%) in quartile four. The difference in 
the absolute risk reduction between the extreme risk quartile ranged from -3.2 to 
28.3% (median= 7.7%; IQR= 0.3-11.3). cOnclusiOns: Clinically significant HTE is 
common even in phase 3 “efficacy” trials on the absolute scale. A multivariate risk 
stratified approach to subgroup analysis is feasible and often clinically informative 
when assessing treatment efficacy.
PRM5
non-tReatMent sPecific PaRaMeteR value estiMates: RelationshiP 
betWeen bMi and utility
Halfpenny N.J.A.1, Quigley J.M.1, Donatti C.2, Hawkins N.S.1
1ICON Health Economics, Oxford, UK, 2Janssen-Cilag UK, High Wycombe, UK
Objectives: Cost-effectiveness models are an important component of health 
economic evaluation. In addition to estimates of treatment effects (typically 
estimated for RCTs), cost-effectiveness estimates may be sensitive to estimates of 
non-treatment specific parameters that describe the relationship between model 
variables. These may be estimated from epidemiological studies that themselves 
include covariable adjustment in order to account for potential confounding. We use 
the example of the estimated relationship between BMI and utility as to illustrate 
methods for the review meta-analysis of parameter estimates arising from multi-
ple studies and issues around the selection of appropriate estimates. MethOds: 
A targeted search was carried out in MEDLINE and EMBASE for studies with utility 
data on BMI. The outcome was utility change per unit increase in BMI. Study charac-
teristics recorded included the utility instrument used, study location, diabetes sta-
tus and number of covariates. Fixed and random effects models as well as graphical 
methods were used to investigate the influence of study characteristics. Results: 
Several utility scales were used throughout with some using multiple utility scales 
within the study to assess quality of life. EQ5-D and SF-6D were the most com-
monly used utility scales. Using a random effects model we observed a change 
in utility per unit increase in BMI of -0.0054 [-0.0077; -0.0031]. However there was 
significant heterogeneity between studies. The number of covariates ranged greatly 
between the studies and appeared predictive of the magnitude of effect of BMI on 
utility. cOnclusiOns: We illustrate methods for meta-analysing multiple param-
eter estimates and discuss the selection of appropriate parameter estimates for the 
inclusion in cost-effectiveness models. In particular we illustrate the relationship 
between the selection of appropriate parameter estimates in terms of which covari-
ables were included in the originating studies and the cost-effectiveness model 
structure in terms of which independent causal effects are modelled.
PRM6
coMPaRison of iqWig and g-ba benefit Ratings in oncology
Schuchardt M.1, Khoury C.2, Friedmann B.3, Haigh J.4
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Objectives: This research was conducted to understand key reasons why the G-BA 
came to a different benefit rating than IQWiG during oncology HTAs. MethOds: 
Searching the G-BA and IQWiG homepages, oncology HTAs between 1st of January 
2011 and 31st of December 2013 have been identified. Assessments for which the 
G-BA attested a benefit rating divergent from the one proposed by IQWiG have been 
analyzed to reveal the key reasons for difference. Results: In the observed time 
frame, 18 HTAs of oncology products have been conducted by IQWiG and G-BA in 
Germany. IQWiG and G-BA were aligned in their benefit ratings in 14 reports (78%). 
During four assessments (22%) the G-BA came to a different conclusion than IQWiG. 
These are the assessments of crizotinib, eribulin, pertuzumab and the resubmission 
for vandentanib. One reason for different ratings observed in three assessments 
is that the G-BA looked at time-adjusted analyses to correct for different lengths 
of treatment in the trial arms. The extend of benefit that is extracted from the 
same data also potentially differs. This is exemplified by the case of vandentanib, 
where the G-BA was more convinced by the data on “time to worsening of pain” 
than IQWiG and attested a “minor benefit” (as compared to “no added benefit”). 
In the case of eribulin, G-BA and IQWiG agreed on benefit based on survival data. 
Due to the potential side effects however, G-BA demoted to “minor”, while IQWiG 
initially demoted to “no added benefit”. cOnclusiOns: The translation of clinical 
evidence into a benefit rating and weighing of positive versus negative effects is 
highly complex. We see that G-BA and IQWiG can come to different conclusions. In 
all cases it is important that the manufacturer shows evidence against the speci-
fied comparator. The benefit rating plays an important role in the reimbursement 
amount negotiations.
PRM7
suRvival status in (PhaRMaco) ePideMiological studies can be 
successfully investigated using adMinistRative Residential 
RegistRies
Potthoff P., Eichmann F., Klamert A.
Kantar Health Germany, Munich, Germany
Objectives: Study subject survival is a key outcome and endpoint in pharmacoepi-
demiological studies. When participants in long-term studies drop out, administra-
tive residential registries can be a useful source to investigate subjects’ vital status. 
The present contribution reports procedures and results of vital status inquiries 
in German administrative residential databases. A pharmacoepidemiological and 
an environmental exposure study are used as case studies. MethOds: For both 
case studies, residential addresses of study participants were submitted to the 
responsible official residential register with the purpose of collecting information 
about vital status or – in case of address changes – the new address was collected. 
For persons with multiple address changes up to 7 inquiry loops were necessary 
until vital status could be ascertained. Results: In the environmental case study 
assessing effects of an urban chemical accident, 20.170 addresses of German citizens 
